Pluristem granted approval to test placenta cell-based therapy in Israel

10/4/2013 | Pharmaceutical Business Review Online

Pluristem Therapeutics obtained clearance from the Israeli Ministry of Health to initiate a midstage trial of its PLacental eXpanded cells in patients with intermittent claudication. The trial in Israel will follow the same protocol used by Pluristem in its U.S. study, which involved around 150 patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC